Eritrea Eliminates Trachoma as Public Health Problem
The World Health Organization validated Eritrea's elimination of trachoma as a public health problem on November 16, 2026. Eritrea is the 11th country in the WHO African Region and the 34th worldwide to reach the threshold against the world's leading infectious cause of blindness.
Edited and fact-checked by Stephen Sprague
The WHO has validated Eritrea's elimination of trachoma as a public health problem after two decades of surveys, surgery and antibiotics, and surveillance continues so new cases are still caught.
The World Health Organization has validated Eritrea's elimination of trachoma as a public health problem, the agency announced on November 16, 2026.
The wording matters, and it has a precise meaning. Validation doesn't mean the bacterium is gone from Eritrea. It means an independent, WHO-appointed dossier review group examined the country's evidence and confirmed that infection rates and untreated advanced cases have fallen below the agreed epidemiological thresholds, and that systems exist to detect and manage new cases. Eritrea is the 11th country in the WHO African Region and the 34th globally to meet that standard.
Trachoma is caused by the bacterium Chlamydia trachomatis. It spreads through contact with eye and nasal discharge from infected people. Repeated infections scar the inner eyelid until the eyelashes turn inward and scrape the cornea, a late stage called trichiasis. That scraping is what blinds. Trachoma remains the world's leading infectious cause of blindness, and it tracks poverty closely, because transmission thrives where water, sanitation and health care are hard to reach.
Eritrea's program ran for two decades. Baseline surveys between 2006 and 2020 covered all 58 sub-zobas, the country's second-level administrative areas, and health workers used digital mapping tools to find affected communities, including remote ones. Interventions followed the WHO's SAFE strategy: surgery for trichiasis, antibiotics to clear infection, facial cleanliness to reduce transmission, and environmental improvement, particularly water and sanitation. The antibiotics were predominantly oral azithromycin, donated by Pfizer through the International Trachoma Initiative.
The Fred Hollows Foundation, one of the partners in the program, dated the organized effort to the creation of Eritrea's National Blindness Prevention Program in 2006. The foundation said Eritrea tailored its elimination activities to local conditions rather than importing a fixed model, and it worked alongside the Ministry of Health, UNICEF, the International Trachoma Initiative and the END Fund.
"After two decades of determined effort, Eritrea has consigned trachoma as a public health problem to history," said Dr. Tedros Adhanom Ghebreyesus, the WHO Director-General. Dr. Mary Stephen, the WHO Representative to Eritrea, credited national leadership and community-level work, and she noted that the country achieved significant gains with limited external funding, using a community-led sanitation approach.
Eritrea also became the 66th country globally, and the 23rd in the African Region, to have eliminated at least one neglected tropical disease. The global picture shows why each validation is slow work. The population requiring trachoma interventions fell from an estimated 1.5 billion in 2002 to below 100 million by November 2025, a reduction of about 94 percent. But as of March 2026, 92 million people still lived in trachoma-endemic areas across 29 countries where the disease remains a public health problem. In 2025 alone, 98,829 people received surgery for the advanced stage and 47.4 million people received antibiotics.
Validation isn't the end of the program. Eritrea has established systems to identify and manage new trichiasis cases, and surveillance continues after validation, because a disease pushed below a threshold can return if the conditions that spread it come back. The WHO said it will keep working with the government to sustain the result.
Sources
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.